Protagonist Therapeutics, Inc.
PTGX
$65.14
-$2.28-3.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -69.38% | -65.34% | 448.54% | 221.61% | 223.50% |
| Total Depreciation and Amortization | -15.07% | -12.64% | -12.59% | -3.89% | 0.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.29% | 24.22% | 15.09% | 13.75% | 6.84% |
| Change in Net Operating Assets | -253.90% | 196.29% | -528.41% | 583.15% | 527.95% |
| Cash from Operations | -82.92% | 632.15% | 362.19% | 293.80% | 297.19% |
| Capital Expenditure | -252.53% | -97.15% | -122.50% | -61.21% | -65.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -62.98% | -844.46% | -671.37% | -1,418.29% | -260.67% |
| Cash from Investing | -63.82% | -829.85% | -662.86% | -1,455.90% | -262.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -33.07% | -79.95% | -84.55% | -86.60% | -66.18% |
| Repurchase of Common Stock | 20.17% | 62.25% | 21.98% | 21.98% | 22.18% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -33.24% | -80.10% | -84.83% | -86.89% | -66.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -255.52% | -173.34% | -246.73% | -227.92% | 4.44% |